# FDA Approves Klygefa, First Dual-Binding Nanobody Drug for Myasthenia Gravis

URL: https://edufabtech.com/news/fda-approves-klygefa-gefurulimab-myasthenia-gravis  
Section: News · Health  
Published: 2026-11-17  
Publisher: EduFabTech (https://edufabtech.com)

> The FDA approved Klygefa (gefurulimab) on 16 November 2026 for generalized myasthenia gravis in AChR antibody-positive adults, based on the 260-patient PREVAIL trial reported in JAMA Neurology.

The US Food and Drug Administration approved Klygefa (gefurulimab-gaks) on 16 November 2026 for adults with generalized myasthenia gravis who test positive for acetylcholine receptor (AChR) antibodies, according to a press release from the Muscular Dystrophy Association (2026). The drug, developed by Alexion, AstraZeneca Rare Disease, is described by the MDA as the first and only dual-binding nanobody C5 inhibitor approved for the condition.

## A Disease With Few Convenient Options

Generalized myasthenia gravis is an autoimmune disorder in which antibodies disrupt signaling at the neuromuscular junction, causing fluctuating muscle weakness that can affect the eyes, limbs, swallowing and breathing. Several complement C5 inhibitors are already approved for AChR antibody-positive patients, but existing options require intravenous infusion every two to eight weeks or, in the case of other subcutaneous drugs, daily dosing, according to the Muscular Dystrophy Association (2026).

Klygefa is designed to change that dosing burden. It binds complement protein C5 at two separate sites and also binds serum albumin, which extends its half-life enough to allow once-weekly subcutaneous self-injection through an autoinjector, with a weight-based loading dose on day one followed by weekly maintenance dosing from day eight, as reported by BioPharm International (2026).

![Grouped bar chart comparing gefurulimab to placebo on the MG-ADL, QMG, and MGC improvement scores from the PREVAIL trial at week 26.](https://edufabtech.com/uploads/2026/11/fda-approves-klygefa-gefurulimab-myasthenia-gravis-2.png)
*Grouped bar chart comparing gefurulimab to placebo on the MG-ADL, QMG, and MGC improvement scores from the PREVAIL trial at week 26. — EduFabTech · Own work*

## What the PREVAIL Trial Measured

The approval rests on the Phase 3 PREVAIL trial, published in *JAMA Neurology* by Kelly G. Gwathmey of Virginia Commonwealth University, Francesco Saccà of the University of Naples Federico II, James F. Howard Jr of the University of North Carolina and co-authors (JAMA Neurology, 2026). The randomized, double-blind, placebo-controlled study screened 405 patients at 113 sites in 20 countries and randomized 260 of them, 131 to gefurulimab and 129 to placebo, for a 26-week controlled treatment period followed by an optional open-label extension.

On the primary endpoint, change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score at week 26, gefurulimab recipients improved by 4.2 points (95% CI, −4.7 to −3.6) compared with 2.6 points (95% CI, −3.1 to −2.0) on placebo, a treatment difference of 1.6 points (P < .001), the paper reports. The authors note that a clinically meaningful separation from placebo appeared as early as week one.

## Secondary Measures and Safety

On the Quantitative Myasthenia Gravis (QMG) score, a secondary endpoint, gefurulimab improved scores by 4.5 points (95% CI, −5.2 to −3.8) versus 2.4 points (95% CI, −3.1 to −1.7) on placebo, a difference of 2.1 points (P < .001). A five-point or greater QMG reduction was reached by 46.3% of gefurulimab patients versus 25.2% on placebo (odds ratio 2.56, P = .002), and a three-point or greater MG-ADL reduction was reached by 65.5% versus 52.2% (odds ratio 1.74, P = .04). The Myasthenia Gravis Composite score improved by 7.8 points versus 4.7 points (P < .001), according to the trial report in JAMA Neurology (2026).

Adverse events occurred in 75.6% of gefurulimab recipients and 80.6% of placebo recipients, mostly mild to moderate, with injection-site reactions, headache, back pain and nasopharyngitis the most common events tied to treatment. Serious adverse events occurred in 9.2% of the gefurulimab group versus 11.6% of the placebo group, and the authors report no meningococcal infections in either arm, a known risk with C5-targeted drugs. The paper concludes that gefurulimab "demonstrated both early and sustained clinical benefit in AChR-Ab+ gMG and was well tolerated, supporting its potential as a convenient, once-weekly, self-administered treatment regimen," per JAMA Neurology (2026).

![A three-step timeline of Klygefa's dosing schedule, from the day-one weight-based loading dose through day-eight maintenance to ongoing once-weekly self-injection.](https://edufabtech.com/uploads/2026/11/fda-approves-klygefa-gefurulimab-myasthenia-gravis-3.png)
*A three-step timeline of Klygefa's dosing schedule, from the day-one weight-based loading dose through day-eight maintenance to ongoing once-weekly self-injection. — EduFabTech · Own work*

## What the Approval Means for Patients and Researchers

The Muscular Dystrophy Association's chief research officer, Angela Lek, said in the organisation's statement that "each new therapy brings us closer to more personalized and effective treatment approaches," while MDA ambassador Elizabeth Madole, who lives with myasthenia gravis, said "every new treatment option brings renewed hope and the possibility of finding approaches that work better for more people," according to the Muscular Dystrophy Association (2026).

For researchers studying neuromuscular disease and complement biology, PREVAIL adds a dual-binding, albumin-extended nanobody to the C5-inhibitor class already represented by eculizumab, ravulizumab and zilucoplan, with 26 weeks of randomized controlled data and an ongoing open-label extension still generating longer-term safety and durability evidence, as described in the trial publication in JAMA Neurology (2026).

## Sources

1. Kelly G. Gwathmey, Francesco Saccà, James F. Howard Jr, et al.. (2026). Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. JAMA Neurology https://doi.org/10.1001/jamaneurol.2026.2333
2. Muscular Dystrophy Association. (2026). FDA Approves KLYGEFA™ (gefurulimab-gaks), Expanding Treatment Options for Generalized Myasthenia Gravis. Muscular Dystrophy Association https://www.mda.org/press-releases/fda-approves-klygefa-expanding-treatment-options-for-generalized-myasthenia-gravis
3. BioPharm International Editors. (2026). FDA Approves AstraZeneca's Gefurulimab (Klygefa) for Generalized MG. BioPharm International https://www.biopharminternational.com/view/fda-approves-astrazeneca-gefurulimab-klygefa-generalized-myasthenia-gravis

---
Source page: https://edufabtech.com/news/fda-approves-klygefa-gefurulimab-myasthenia-gravis  
Quote with a link to the source page. © EduFabTech.
